Identifying Blood-Based Markers for Optimized Bipolar Androgen Therapy in mCRPC

[madman]

Samuel Denmeade, MD, of Johns Hopkins University School of Medicine, highlights his research on blood-based markers of differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial.

This research was presented as a late-breaking abstract at the 2024 American Society of Clinical Oncology Annual Meeting.

 

[madman]

 

[madman]

 

[madman]

 

[madman]

 

[madman]

 

[madman]

Bipolar androgen therapy in prostate cancer: Current evidence and next steps

"We've been doing a lot of work at Johns Hopkins using high-dose testosterone therapies to treat patients with metastatic prostate cancer," says Mark C. Markowski, MD, PhD. https://www.urologytimes.com/view/bipolar-androgen-therapy-in-prostate-cancer-current-evidence-and-next-steps In this...

www.excelmale.com

 

[madman]

Dr. Samuel Denmeade on Bipolar Androgen Therapy for Prostate Cancer

* This approach involves administering high doses of testosterone, which has shown significant improvement in 30% of patients, enhancing strength, energy, and sexual function * their research uses blood-based DNA markers to predict which patients will respond best, aiming to personalize...

www.excelmale.com